Back to search results

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

Abroad (travel likely)RecruitingPHASE2

Conditions

Neuroendocrine Tumors · Neuroendocrine Tumor Grade 1 · Neuroendocrine Tumor Grade 2

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States

    Contact: Study coordinator (Kristin Gaimari-Varner, RN, BSN) · kristin-gaimari-varner@uiowa.edu · 319-384-9495
    Contact: Study coordinator (Kellie Bodeker, Ph.D.) · kellie-bodeker@uiowa.edu · 319-384-9425
    David Bushnell, MD (Sub-investigator)
    Yusuf Menda, MD (Sub-investigator)
    Janet Pollard, MD (Sub-investigator)
    Parren McNeely, MD (Sub-investigator)
    Michael Graham, MD, PhD (Sub-investigator)
    Kristin Plichta, MD, PhD (Sub-investigator)
    Contact: Principal Investigator (Stephen Graves, PhD)
Study leads

  • Stephen Graves, Ph.D., DABR

    Principal Investigator

    University of Iowa

View source on ClinicalTrials.gov(opens in a new tab)